

Application No.: 09/887,593

Docket No.: 511582001810

CLAIMS AMENDMENT

1-71. (canceled)

72. (currently amended): A method of inhibiting cells that express 19P1E8 activity, comprising:

administering to a cell that expresses 19P1E8 an effective amount of a composition capable of inhibiting 19P1E8 activity, whereby the composition inhibits 19P1E8 binding or inhibits expression of 19P1E8 from the cell;

wherein 19P1E8 encodes a protein having at least 90% identity to SEQ ID NO: 2.

73-79. (canceled)

80. (previously presented): A method of treating a subject, comprising:

administering to the subject an effective amount of a composition capable of inhibiting cells that express 19P1E8 (SEQ ID NO: 2) activity to the subject, whereby the composition inhibits 19P1E8 binding or inhibits expression of 19P1E8;

wherein 19P1E8 encodes a protein having at least 90% identity to SEQ ID NO: 2.

81-89. (canceled)

90. (previously presented): The method of claim 72, wherein said administering is to cells *ex vivo*.

91. (previously presented): The method of claim 72, wherein said administering is to cells *in vivo*.

92. (previously presented): The method of claim 80, wherein said administering is to cells *ex vivo*.

Application No.: 09/887,593

Docket No.: 511582001810

93. (previously presented): The method of claim 80, wherein said administering is to cells *in vivo*.

94. (previously presented): The method of claim 72, wherein the composition comprises an antibody that binds to 19P1E8.

95. (previously presented): The method of claim 94, wherein the antibody is a monoclonal antibody.

96. (previously presented): The method of claim 94, wherein the antibody is a polyclonal antibody

97. (previously presented): The method of claim 94, wherein the antibody is a chimeric antibody.

98. (previously presented): The method of claim 94, wherein the antibody is a humanized antibody.

99. (previously presented): The method of claim 94, wherein the antibody comprises an antibody fragment selected from the group consisting of a Fab, a F(ab')₂, a Fv and a sFv fragment.

100. (previously presented): The method of claim 80, wherein the composition comprises an antibody that binds to 19P1E8.

101. (previously presented): The method of claim 100, wherein the antibody is a monoclonal antibody.

102. (currently amended): The method of claim 100, wherein the antibody is a polyclonal antibody.

Application No.: 09/887,593

Docket No.: 511582001810

103. (previously presented): The method of claim 100, wherein the antibody is a chimeric antibody.

104. (previously presented): The method of claim 100, wherein the antibody is a humanized antibody.

105. (previously presented): The method of claim 100, wherein the antibody comprises an antibody fragment selected from the group consisting of a Fab, a F(ab')₂, a Fv and a sFv fragment.